Liraglutide reverses pronounced insulin-associated weight gain, improves glycaemic control and decreases insulin dose in patients with type 2 diabetes: a 26 week, randomised clinical trial (ELEGANT).

What the trial testedas reported · 50 people · 2014

Not counted

−5.20kg−6.70 to −3.60

As reported

difference −5.2 kg, 95% CI −6.70 to −3.60

the abstract, start to end

… with standard therapy (mean difference -5.2 kg [95% CI -6.7, -3.6 kg]; p < …

← favours treatmentfavours comparator →

could be chance

Body weight & composition

−5.2−6.70 to −3.60

GLP-1 receptor agonistsBody weight & composition

1 / 3

2014

2015

2016

2017

2018

2019

2020

2021

2022

2023

2024

2025

2026

this paperpooled ittrialcites it